Cyxone AB (Sweden) Performance
| CYXO Stock | SEK 0.03 0.01 21.57% |
On a scale of 0 to 100, Cyxone AB holds a performance score of 2. The firm shows a Beta (market volatility) of -1.95, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Cyxone AB are expected to decrease by larger amounts. On the other hand, during market turmoil, Cyxone AB is expected to outperform it. Please check Cyxone AB's maximum drawdown, potential upside, and the relationship between the treynor ratio and value at risk , to make a quick decision on whether Cyxone AB's price patterns will revert.
Risk-Adjusted Performance
2 of 100
Weak | Strong |
Very Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Cyxone AB are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain basic indicators, Cyxone AB unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 56.3 M | |
| Total Cashflows From Investing Activities | -892 K |
Cyxone |
Cyxone AB Relative Risk vs. Return Landscape
If you would invest 4.20 in Cyxone AB on August 30, 2024 and sell it today you would lose (1.10) from holding Cyxone AB or give up 26.19% of portfolio value over 90 days. Cyxone AB is generating 0.3538% of daily returns and assumes 13.6341% volatility on return distribution over the 90 days horizon. Simply put, majority of traded equity instruments are less risky than Cyxone on the basis of their historical return distribution, and most equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Cyxone AB Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cyxone AB's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Cyxone AB, and traders can use it to determine the average amount a Cyxone AB's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0259
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | CYXO | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 13.63 actual daily | 96 96% of assets are less volatile |
Expected Return
| 0.35 actual daily | 6 94% of assets have higher returns |
Risk-Adjusted Return
| 0.03 actual daily | 2 98% of assets perform better |
Based on monthly moving average Cyxone AB is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cyxone AB by adding it to a well-diversified portfolio.
Cyxone AB Fundamentals Growth
Cyxone Stock prices reflect investors' perceptions of the future prospects and financial health of Cyxone AB, and Cyxone AB fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cyxone Stock performance.
| Return On Equity | -1.07 | |||
| Return On Asset | -0.59 | |||
| Current Valuation | 7.74 M | |||
| Shares Outstanding | 98.44 M | |||
| Price To Book | 1.00 X | |||
| Price To Sales | 5,168 X | |||
| EBITDA | (43.23 M) | |||
| Cash And Equivalents | 56.34 M | |||
| Cash Per Share | 0.97 X | |||
| Book Value Per Share | 0.50 X | |||
| Cash Flow From Operations | (43.25 M) | |||
| Earnings Per Share | (0.76) X | |||
| Total Asset | 46.13 M | |||
About Cyxone AB Performance
Assessing Cyxone AB's fundamental ratios provides investors with valuable insights into Cyxone AB's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Cyxone AB is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Cyxone AB , a clinical biotech company, develops disease modifying therapies for rheumatoid arthritis and multiple sclerosis and treatments for virally induced acute respiratory disorders. The company was founded in 2015 and is headquartered in Malm, Sweden. Cyxone AB is traded on Stockholm Stock Exchange in Sweden.Things to note about Cyxone AB performance evaluation
Checking the ongoing alerts about Cyxone AB for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cyxone AB help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cyxone AB had very high historical volatility over the last 90 days | |
| Cyxone AB has some characteristics of a very speculative penny stock | |
| Cyxone AB has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (45.03 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Cyxone AB has accumulated about 56.34 M in cash with (43.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.97, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 25.0% of the company shares are held by company insiders |
- Analyzing Cyxone AB's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cyxone AB's stock is overvalued or undervalued compared to its peers.
- Examining Cyxone AB's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cyxone AB's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cyxone AB's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cyxone AB's stock. These opinions can provide insight into Cyxone AB's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Cyxone Stock Analysis
When running Cyxone AB's price analysis, check to measure Cyxone AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyxone AB is operating at the current time. Most of Cyxone AB's value examination focuses on studying past and present price action to predict the probability of Cyxone AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cyxone AB's price. Additionally, you may evaluate how the addition of Cyxone AB to your portfolios can decrease your overall portfolio volatility.